Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is predictive of primary and pregnancy thrombotic thrombocytopenic purpura;Afwezige activiteit van Von Willebrand-factorsplitsend eiwit (ADAMTS-13) diagnostisch voor primaire en zwangerschapsgerelateerde trombotische trombocytopenische purpura

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 40, 2004, Pages 1972-1976

  Hulstein, J J ^a   Rison, C N ^a   Kappers Klunne, M C ^c   Hene, R J ^a   Franx, A ^a   De Groot, Ph G ^a   Brand, A ^d   Fijnheer, R ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOSPORIN; LACTATE DEHYDROGENASE; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREDICTION; PREGNANCY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; FEMALE; HELLP SYNDROME; HUMANS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 5044240513     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
2. Lara jr PN, Coe TL, Zhou H, Fernando L, Holland PV. Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999;107:573-9.
3. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14:495-504.
4. Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001;113:58-64.
5. Rock GA, Shumak RK, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-7.
6. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992;80:1890-5.
7. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-103.
8. Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med 2002;80:639-47.
9. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-46.
10. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
11. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
12. Kappers-Klunne MC, Meulen JHP van der, Holdrinet RSG, Meer J van der, Wijermans PW, Brand A. Trombotische trombocytopenische purpura in 13 Nederlandse centra: behandeling en beloop. Ned Tijdschr Geneeskd 1997;141:1192-6.
13. Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993;7:94-103.
14. Plas RM van der, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798-802.
15. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
16. Tsai HM. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2002;100:3839-40.
17. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-8.
18. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87: 4223-34.
19. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997;89:1954-62.
20. Lawrie AS, Hoser MJ. Savidge GF. Phast assessment of vWf:Ag multimeric distribution. Thromb Res 1990;59:369-73.